• Beacon VP Capital uses a primarily event-driven approach to investing in order to generate returns that are less correlated with the broader financial markets. 
     
  • Beacon VP Capital invests primarily in lesser known, micro to mid-cap biotechnology and pharmaceutical companies with pharmaceutical drugs at or near the final stage of the Food and Drug Administration (FDA) approval process.
  • We use published clinical data to analyze the underlying science of a drug going through the United States Food and Drug Administration (“FDA”) approval process.

  • Beacon VP Capital achieves these investment objectives by pursuing an investment strategy focused on scientific analysis, proprietary research and collective intelligence.
     
  • Beacon VP Capital's science based investments consist principally of a combination of securities and derivatives issued by micro to mid-cap biotechnology and pharmaceutical companies primarily operating in the United States.
  • We screen companies with scheduled FDA events and then apply our research framework to identify drugs that have a high efficacy-to-safety ratio. Our data sources include primary scientific literature, company presentations, and SEC filings.